Balraj Saini

Balraj Saini

Auto-generated profile, based on publicly available information

Balraj Saini

Chitkara College of Pharmacy, Chitkara University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2020 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
DLDamanpreet Kaur Lang
Damanpreet Kaur Lang
Rajwinder KaurRajwinder Kaur
Rajwinder Kaur
RARashmi Arora
Rashmi Arora
BSBalraj Saini
Balraj Saini
SASandeep Arora
Sandeep Arora
Background: Cancer is spreading all over the world, and it is becoming the leading cause of major deaths. Today’s most difficult task for every researcher is to invent a new drug that can treat cancer with minimal side effects. Many factors, including pollution, modern lifestyle and food habits, exposure to oncogenic agents or radiations, enhanced industrialization, etc. can cause cancer. Treatment of cancer is done by various methods that include chemotherapy, radiotherapy, surgery and immunotherapy in combination or singly along with kinase inhibitors. Most of the anti-cancer drugs use the concept of kinase inhibition. Objective: The number of drugs being used in chemotherapy has heterocycles as their basic structure in spite of various side effects. Medicinal chemists are focusing on nitrogen-containing heterocyclic compounds like pyrrole, pyrrolidine, pyridine, imidazole, pyrimidines, pyrazole, indole, quinoline, oxadiazole, azole, benzimidazole, etc. as the key building blocks to develop active biological compounds. The aim of this study is to attempt to compile a dataset of nitrogen-containing heterocyclic anti-cancer drugs. Methods: We adopted a structural search on notorious journal publication websites and electronic databases such as Bentham Science, Science Direct, PubMed, Scopus, USFDA, etc. for the collection of peer-reviewed research and review articles for the present review. The quality papers were retrieved, studied, categorized into different sections, analyzed and used for article writing. Conclusion: As per FDA databases, nitrogen-based heterocycles in the drug design are almost 60% of unique small-molecule drugs. Some of the nitrogen-containing heterocyclic anti-cancer drugs are Axitinib, Bosutinib, Cediranib, Dasatanib (Sprycel®), Erlotinib (Tarceva®), Gefitinib (Iressa®), Imatinib (Gleevec®), Lapatinib (Tykerb ®), Linifanib, Sorafenib (Nexavar®), Sunitinib (Sutent®), Tivozanib, etc. In the present review, we shall focus on the overview of nitrogen-containing heterocyclic active compounds as anti-cancer agents.

15 May 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
Rajwinder KaurRajwinder Kaur
Rajwinder Kaur
KKKirandeep Kaur
Kirandeep Kaur
Mohammad H. AlyamiMohammad H. Alyami
Mohammad H. Alyami
DLDAMANPREET KAUR LANG
DAMANPREET KAUR LANG
BSBalraj Saini
Balraj Saini
BCBalakumar Chandrasekaran
Balakumar Chandrasekaran
The nature of microorganisms and the efficiency of antimicrobials have witnessed a huge co-dependent change in their dynamics over the last few decades. On the other side, metals and metallic compounds have gained popularity owing to their effectiveness against various microbial strains. A structured search of both research and review papers was conducted via different electronic databases, such as PubMed, Bentham, Springer, and Science Direct, among others, for the present review. Along with these, marketed products, patents, and Clinicaltrials.gov were also referred to for our review. Different microbes such as bacteria, fungi, etc., and their diverse species and strains have been reviewed and found to be sensitive to metal-carrying formulations. The products are observed to restrict growth, multiplication, and biofilm formation effectively and adequately. Silver has an apt use in this area of treatment and recovery, and other metals like copper, gold, iron, and gallium have also been observed to generate antimicrobial activity. The present review identified membrane disruption, oxidative stress, and interaction with proteins and enzymes to be the primary microbicidal processes. Elaborating the action, nanoparticles and nanosystems are shown to work in our favor in well excelled and rational ways.

1 January 2021 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
Rajwinder KaurRajwinder Kaur
Rajwinder Kaur
PDPran Kishore Deb
Pran Kishore Deb
VDVishal Diwan
Vishal Diwan
BSBalraj Saini
Balraj Saini
Background: An endo-β-glucuronidase enzyme, Heparanase (HPSE), degrades the side chains of polymeric heparan sulfate (HS), a glycosaminoglycan formed by alternate repetitive units of D-glucosamine and D-glucuronic acid/L-iduronic acid. HS is a major component of the extracellular matrix and basement membranes and has been implicated in processes of the tissue’s integrity and functional state. The degradation of HS by HPSE enzyme leads to conditions like inflammation, angiogenesis, and metastasis. An elevated HPSE expression with a poor prognosis and its multiple roles in tumor growth and metastasis has attracted significant interest for its inhibition as a potential anti-neoplastic target. Methods: We reviewed the literature from journal publication websites and electronic databases such as Bentham, Science Direct, PubMed, Scopus, USFDA, etc., about HPSE, its structure, functions, and role in cancer. Results: The present review is focused on Heparanase inhibitors (HPIns) that have been isolated from natural resources or chemically synthesized as new therapeutics for metastatic tumors and chronic inflammatory diseases in recent years. The recent developments made in the HPSE structure and function are also discussed, which can lead to the future design of HPIns with more potency and specificity for the target. Conclusion: HPIns can be a better target to be explored against various cancers.

15 April 2021 in Current Bioactive Compounds
Verified
Journal Article
Closed access
PDF file
Rajwinder KaurRajwinder Kaur
Rajwinder Kaur
KKKirandeep Kaur
Kirandeep Kaur
RARashmi Arora
Rashmi Arora
BSBalraj Saini
Balraj Saini
SASandeep Arora
Sandeep Arora
Background: In the last two decades, the flavonoids containing fused heterocyclic nucleus in their chemical structure have emerged to display a variety of pharmacological effects including antiallergic and anti-inflammatory the most recent to the list. These polyphenolic compounds exert their pharmacological effect by various mechanisms including inhibition of human neutrophil elastase, cytokines (Interleukins- IL-3 and IL-4) and mast cells. Methods: We adopted a structured search of notorious journal publication websites and electronic databases such as Science Direct, Bentham, Scopus, PubMed, Nature, Springer etc. for the collection of peer-reviewed research and review articles for the present review. The quality papers (109) were retrieved, studied, categorized into different sections, analyzed and used for article writing. Results: The backbone of this review article is based on four review articles of natural phenolics. Seventeen papers out of total one hundred and nine were about Quercetin the main molecule of interest, five papers outlined the potential benefits of Pycnogenol, Rutin was discussed in detail by considering eight papers in mind, Kaempferol which can be considered as a candidate of interest was referred from six articles. Conclusion: This review identified the Quercetin, Pycnogenol, Rutin and Kampferol as few bioflavonols out of hundreds of other compounds still under clinical trials that have been studied most. Marketed formulations of Pycnogenol are also available as nutraceuticals. These flavonoids have been also reported to the other pharmacological effects like anti-cancer, anti-oxidants, anti-hypertensive, antiviral, anti-ulcerogenic, anti-platelet, anti-hypotensive and anti-hepatotoxic. With all these versatile properties heterocyclic containing flavonoids may be a powerful candidate for the discovery of their utilization in other ailments like asthma.

4 September 2024 in Polymers
Verified
Journal Article
Open access
PDF file
JSJangjeet Karan Singh
Jangjeet Karan Singh
SKSIMRAN KAUR
SIMRAN KAUR
BCBalakumar Chandrasekaran
Balakumar Chandrasekaran
GKGurpreet Kaur
Gurpreet Kaur
BSBalraj Saini
Balraj Saini
PBPallavi Bassi
Pallavi Bassi
The current study focuses on development of phospholipid complex-loaded films of etodolac for enhanced transdermal permeation and anti-inflammatory effect. An etodolac–phospholipid complex was developed using the solvent evaporation method and was characterized by DSC, XRD, FTIR, and 1H-NMR studies. The formation of the complex led to conversion of a crystalline drug to an amorphous form. A stoichiometric ratio of 1:1 (drug–phospholipid) was selected as the optimized ratio. Further, the developed complex was incorporated into films and systematic optimization using a central composite design was carried out using a response surface methodological approach. The desirable design space based on minimum contact angle and maximum tensile strength was selected, while the water vapour transmission rate and swelling index were set within limits. The results for swelling index, contact angle, tensile strength, and water vapour transmission rate were 60.14 ± 1.01%, 31.6 ± 0.03, 2.44 ± 0.39 kg/cm2, and 15.38 g/hm2, respectively. These values exhibited a good correlation with the model-predicted values. The optimized formulation exhibited improved diffusion and permeation across skin. In vivo studies revealed enhanced anti-inflammatory potential of the developed films in comparison to the un-complexed drug. Hence, the study demonstrated that etodolac–phospholipid complex-loaded films improve the transdermal permeation and provided enhanced anti-inflammatory effect.

1 June 2021 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Rajwinder KaurRajwinder Kaur
Rajwinder Kaur
ASAnkita Sood
Ankita Sood
DLDamanpreet Kaur Lang
Damanpreet Kaur Lang
RGRavi Goyal
Ravi Goyal
BSBalraj Saini
Balraj Saini
Schizophrenia is a serious psychiatric disorder leading to cognitive impairment and has higher rates of morbidity and mortality. There is a need to understand the mechanisms underlying the onset and progression of the disease as the clinical presentation may vary in patients and inadequate knowledge of neurochemical alterations can lead to decreased efficacy in treatment which makes it necessary to identify new potent biomarkers. Identification of biomarkers in schizophrenia offers significant benefits to the well-being of patients, including better prognosis, diagnosis, detection, screening, enhancement in treatment efficacy, prevention of relapse, and better clinical results. Incorporation of advanced technological techniques is necessary to provide an approach for the diagnosis and treatment of psychiatric disorders and to permit specific therapeutic interventions. This review highlights the particulars about the current use and application of various biomarkers such as proteomics, miRNAs, language techniques, antibodies, blood biomarkers, gut microbiota, such as analysis, neuroimaging techniques, and inflammatory biomarkers in effective prognosis, detection, and treatment of schizophrenia and which would contribute as an additional tool for a psychiatrist in cases where an appropriate diagnosis is lacking clarity.